Anti-GM antibodies and uses thereof
By targeting the gentamicin antigen epitope with anti-GM antibodies, the problems of rapidity and specificity in the existing technology of gentamicin residue detection are solved, and a rapid and high-precision detection effect is achieved, which is suitable for food safety and environmental monitoring.
Patent Information
- Application Number
- CN202511274383.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-08
- Publication Date
- 2025-10-03
- Estimated Expiration
- 2045-09-08
AI Technical Summary
Existing technologies make it difficult to quickly and accurately detect gentamicin residues. Traditional methods such as LC-MS/MS are cumbersome and time-consuming, while antibodies obtained through hybridoma cell technology have cross-reaction problems and cannot achieve specific detection of gentamicin.
Provides an anti-GM antibody targeting the gentamicin antigen epitope, containing specific complementarity determining regions (CDRs), and is used in enzyme-linked immunosorbent assay (ELISA) and immunochromatography technology to achieve rapid and accurate detection by specifically binding to gentamicin.
It achieves rapid and high-precision detection of gentamicin residues, avoids cross-reactions, and is suitable for food safety supervision and environmental pollution monitoring.
Smart Images

Figure CN120737206A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antibiotic residue immunoassay, and more particularly to an anti-GM antibody and application thereof. Background Art
[0002] Gentamicin (GM) is an aminoglycoside broad-spectrum antibiotic, also referred to as GM in the industry. GM is the standardized abbreviation for gentamicin in the fields of medicine, testing, and scientific research. In specific practices such as antibiotic residue analysis, GM is directly used as the abbreviation and identifier for gentamicin. The so-called anti-GM antibodies are anti-gentamicin antibodies.
[0003] Gentamicin's core bactericidal / inhibitory mechanism lies in inhibiting bacterial protein synthesis and disrupting bacterial cell membrane integrity. Consequently, it exhibits significant bactericidal and inhibitory activity against most Gram-negative and some Gram-positive bacteria, including Escherichia coli, Klebsiella, Salmonella, Shigella, and some subtypes of Staphylococcus aureus (e.g., methicillin-sensitive Staphylococcus aureus MSSA). Furthermore, gentamicin is a heat-stable antibiotic, resulting in a simpler manufacturing process and lower production costs compared to non-heat-stable antibiotics. It also overcomes transportation and storage constraints, not relying on cold chain storage, thus maximizing antibiotic accessibility. Due to these advantages, gentamicin has been widely used in both medical and agricultural applications since its introduction.
[0004] However, as the ototoxicity, nephrotoxicity and other toxic side effects of gentamicin were confirmed, and the problem of drug resistance caused by antibiotic residues became prominent, gentamicin was successively regarded as a restricted antibiotic in the fields of medical care, agricultural breeding, etc. Specifically at the practical level, gentamicin residues were listed as an indicator item of antibiotic residues in the antibiotic residue analysis in related fields such as food safety supervision and environmental pollution monitoring to monitor residual contamination of related substances. However, the traditional liquid chromatography-tandem mass spectrometry (LC-MS / MS) method is cumbersome and time-consuming to operate, and is not conducive to the rapid screening of gentamicin residues in samples. Although the immunoassay method is based on the specific binding of antigens and antibodies and the qualitative / quantitative detection of target substances, both theory and relevant practice support that this type of method can achieve rapid and accurate detection of target substances, but its core tool is a highly specific antibody targeting the target substance. In this regard, directly expressing full-length proteins with complex functions such as antibodies targeting gentamicin antigen epitopes is a core technical challenge in current biopharmaceuticals and basic research on protein expression, which is beyond the reach of current scientific and technological levels. Anti-gentamicin monoclonal antibodies (i.e., anti-GM mAbs) obtained through traditional hybridoma cell technology often have performance variations due to the uncertainty in their preparation process, such as the CCTCC disclosed in CN102776151A. The monoclonal antibodies produced by hybridoma cell line C201135 showed affinity for a variety of aminoglycoside antibiotics, including streptomycin, neomycin, gentamicin, and kanamycin, and were obviously not suitable for specific detection targeting only gentamicin residues. Summary of the Invention
[0005] In view of the above-mentioned problems existing in the prior art, the present invention provides an anti-GM antibody, namely an anti-gentamicin antibody, which targets the gentamicin antigen epitope; it comprises at least one set of complementarity determining regions (CDRs) and specifically binds to the gentamicin antigen epitope. On this basis, a series of applications of the anti-GM antibody in the field of immunoassay technology are proposed, such as a polynucleotide encoding the anti-GM antibody, a kit / non-diagnostic method for detecting gentamicin residues, and the application of the anti-GM antibody, the polynucleotide, the kit / non-diagnostic method in food safety supervision / environmental pollution monitoring, etc.
[0006] The first aspect of the present invention provides an anti-GM antibody.
[0007] The anti-GM antibody provided in the embodiments of the present aspect comprises:
[0008] HCDR1, HCDR2, and HCDR3; HCDR1, HCDR2, and HCDR3 refer to a set of complementarity determining regions (CDRs) of the heavy chain variable region (VH) of the anti-GM antibody; wherein the amino acid sequence of HCDR1 is shown in SEQ ID No. 1; the amino acid sequence of HCDR2 is shown in SEQ ID No. 2; and the amino acid sequence of HCDR3 is shown in SEQ ID No. 3;
[0009] and / or,
[0010] LCDR1, LCDR2, LCDR3; LCDR1, LCDR2, LCDR3 refer to a set of complementarity determining regions (CDRs) of the light chain variable region (VL) of the anti-GM antibody; wherein the amino acid sequence of LCDR1 is shown in SEQ ID No.4; the amino acid sequence of LCDR2 is shown in SEQ ID No.5; and the amino acid sequence of LCDR3 is shown in SEQ ID No.6.
[0011] In a further aspect, in addition to the complementarity determining regions (CDRs), the heavy chain variable region (VH) / light chain variable region (VL) of the antibody further comprises a framework region (FR). Therefore, the anti-GM antibody provided in the embodiments of the present aspect may be: its heavy chain variable region comprises a heavy chain variable region framework region (HFR); the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 7;
[0012] and / or,
[0013] The light chain variable region comprises a light chain variable region framework region (LFR); the amino acid sequence of the light chain variable region is shown in SEQ ID No.8.
[0014] In a further aspect, in addition to the heavy chain variable region / light chain variable region, the antibody may further comprise a constant region (C region). Therefore, the anti-GM antibody provided in the embodiments of the present aspect may further comprise: a heavy chain constant region (CH) and / or a light chain constant region (CL).
[0015] In a further aspect, the antibody can be obtained by stimulating an immune response in an immune model animal, typically a mouse, etc. Therefore, the anti-GM antibody provided in the embodiments of the present aspect can be a murine antibody.
[0016] The second aspect of the present invention provides a polynucleotide encoding the anti-GM antibody described in the first aspect.
[0017] In a further aspect, with respect to the anti-GM antibody of the first aspect, whose amino acid sequence of the heavy chain variable region is shown as SEQ ID No. 7 and / or whose amino acid sequence of the light chain variable region is shown as SEQ ID No. 8, the polynucleotide provided in the embodiments of the current aspect comprises: a nucleotide fragment encoding the heavy chain variable region of the anti-GM antibody, whose sequence is shown as SEQ ID No. 9;
[0018] and / or,
[0019] A nucleotide fragment encoding the light chain variable region of the anti-GM antibody, the sequence of which is shown in SEQ ID No. 10.
[0020] A third aspect of the present invention provides a kit for detecting gentamicin residues.
[0021] The kit for detecting gentamicin residues provided in the embodiments of the present aspect comprises: the anti-GM antibody described in the first aspect, which is intended to capture gentamicin residues by specifically binding to free gentamicin in the sample to be tested; and a reagent for detecting the binding of free gentamicin to the anti-GM antibody, which is intended to convert the specific binding event of free gentamicin to the anti-GM antibody into a detectable signal (such as an optical, electrochemical or colorimetric signal), thereby achieving qualitative or quantitative analysis of gentamicin residues.
[0022] In a further aspect, enzyme-linked immunosorbent assay (ELISA) is a mainstream technology in the field of immunoassay technology; its core is to achieve qualitative and quantitative detection of target substances through solid-phase antibodies / antigens and enzyme labels. The enzyme label refers to a complex formed by the binding of a specific enzyme molecule (such as horseradish peroxidase) and an antibody / antigen, such as an enzyme-labeled secondary antibody, an enzyme-labeled primary antibody, and an enzyme-labeled antigen. Therefore, the kit provided in the embodiments of the present aspect can be an ELISA kit; the ELISA kit includes: a solid-phase carrier pre-coated with the anti-GM antibody, or the enzyme-labeled anti-GM antibody, or the anti-GM antibody and a compatible enzyme-labeled secondary antibody.
[0023] Furthermore, immunochromatographic assay (ICA) is also an important branch of the development of immunoassay technology. It is also based on the core logic of the immunoassay technology framework of antigen-antibody specific binding. Specifically, it mainly uses chromatographic carriers (such as nitrocellulose membranes) to achieve the separation and capture of target substances, thereby realizing the qualitative / quantitative detection of target substances. Among them, the immunochromatographic test strip is the core functional carrier of the immunochromatographic kit, and the immunochromatographic kit mainly carries markers through the conjugate pad (Conjugate Pad) / conjugate zone (Conjugate Zone) of the immunochromatographic test strip or a carrier independent of the immunochromatographic test strip. Therefore, the kit provided in the embodiment of the current aspect can be an immunochromatography kit; the immunochromatography kit includes: an immunochromatography test strip; wherein, the immunochromatography kit is coated with a marker through the binding pad / binding area of the immunochromatography test strip or independently loaded with a marker; the marker is an anti-GM antibody labeled with colorimetric or fluorescent nanoparticles; wherein, the colorimetric nanoparticles are colloidal gold, colloidal carbon or latex microspheres; the fluorescent nanoparticles are quantum dots or fluorescent microspheres.
[0024] A fourth aspect of the present invention provides a non-diagnostic method for detecting gentamicin residues.
[0025] The non-diagnostic method for detecting gentamicin residues provided in the embodiments of the present aspect comprises:
[0026] Incubating the anti-GM antibody described in the first aspect or the anti-GM antibody in the kit for detecting gentamicin residues described in the first aspect with the sample to be tested;
[0027] And further detecting the binding of free gentamicin in the test sample after incubation with the anti-GM antibody, thereby determining the residual gentamicin in the test sample.
[0028] The fifth aspect of the present invention provides an application of the anti-GM antibody described in the first aspect, the polynucleotide described in the second aspect, the kit for detecting gentamicin residues described in the third aspect, or the non-diagnostic method for detecting gentamicin residues described in the fourth aspect in food safety supervision / environmental pollution monitoring.
[0029] The present invention provides an anti-GM antibody (i.e., anti-gentamicin antibody) that specifically targets the gentamicin (GM) antigen epitope, thereby minimizing cross-reactions and achieving competitive recognition and capture of the gentamicin antigen. Furthermore, the present invention applies the anti-GM antibody to the field of immunoassay technology, specifically by providing a polynucleotide encoding the anti-GM antibody, a kit / non-diagnostic method for detecting gentamicin residues, and applications in food safety supervision / environmental pollution monitoring, thereby promoting the rapid and high-precision detection of gentamicin residues in samples. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 SDS-PAGE electrophoresis diagram of the anti-GM antibody 3A3-G3 provided in an embodiment of the present invention;
[0031] Figure 2 Schematic diagram of specificity test results of the gentamicin (GM) rapid test kit provided in an embodiment of the present invention. DETAILED DESCRIPTION
[0032] Unless otherwise defined, the practice of the present invention will employ conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987 edition and periodic updates thereof); PCR: The Polymerase Chain Reaction (Mullis et al., eds., 1994); A Practical Guide to Molecular Cloning (Perbal Bernard V., 1988); Phage Display: A Laboratory Manual (Barbas et al., 2001).
[0033] As used herein, the term "antibody" (Ab) includes monoclonal antibodies (including full-length antibodies having an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, multispecific antibodies (e.g., bispecific antibodies), diabodies, and single-chain molecules, as well as antibody fragments (particularly antigen-binding fragments; an antigen-binding fragment is a functional antibody fragment contained in an antibody that retains the ability to bind to an antigen). As used herein, the terms "immunoglobulin" (Ig) and antibody are used interchangeably.
[0034] The term "antigen" (Ag) includes small-molecule antigens and complete antigens. Small-molecule antigens, also known as haptens or incomplete antigens, primarily refer to compounds with a small molecular weight (usually 100–1000 Da) that lack immunogenicity when present alone but are highly reactogenic, such as drugs, hormones, pesticides, and toxins. "Complete antigens" refer to substances that are both immunogenic and immunoreactive. Complete antigens naturally occur in a wide variety of species and are widely distributed, such as most proteins, bacteria, viruses, bacterial exotoxins, and animal sera. The term "immunogenicity" refers to the ability to stimulate the immune system to produce a specific immune response, while the term "reactogenicity" refers to the ability to specifically bind to immune response products (such as antibodies).
[0035] Gentamicin, as described in the present invention, is a small molecule antigen. Small molecule antigens can acquire immunogenicity by binding to a macromolecular protein carrier, transforming them into complete antigens that are both immunoreactive and immunogenic. The term "protein carrier" refers to any immunologically acceptable protein used to form a complete antigen, including but not limited to bovine serum albumin, ovalbumin, keyhole limpet hemocyanin, human serum albumin (HSA), and synthetic polylysine (PLL), with bovine serum albumin (BSA) or ovalbumin (OVA) being preferred.
[0036] In immunoassay technology, complete antigens can be divided into immunogens and coating antigens based on their functional focus. Immunogens refer to complete antigens that can induce an immune response, while coating antigens refer to complete antigens that are pre-immobilized on the surface of a solid phase carrier during the immunoassay process.
[0037] The variable region or domain (V region) of an antibody refers to the amino-terminal (N-terminal) domain of an antibody's heavy or light chain. The variable regions / domains of the heavy and light chains are referred to as "VH" and "VL," respectively. These domains are typically the most variable parts of an antibody and contain the antigen-binding site.
[0038] The term "variable" refers to the fact that certain segments of the variable region vary widely in antibody sequences. These highly variable segments are usually called complementarity determining regions (CDRs), which are the key fragments in the antibody variable region that directly bind to the antigen and determine the specificity and affinity of the antibody. Generally speaking, a complete antibody molecule contains six CDR segments, namely HCDR1, HCDR2 and HCDR3 of the heavy chain variable region (VH) and LCDR1, LCDR2 and LCDR3 of the light chain variable region (VL). The aforementioned six CDR segments cooperate to form an antigen binding pocket (Paratope) through spatial conformation and jointly recognize antigen epitopes. However, there are exceptions. For example, there is a single-domain antibody (VHH), in which only the heavy chain variable region is included (lacking the light chain, etc.), and antigen binding is achieved only through the three CDR segments (HCDR1, HCDR2, HCDR3) of the heavy chain variable region. In addition to the complementarity determining regions, the relatively conserved part of the variable region is called the framework region (FR); the framework region is intended to provide structural support for the complementarity determining regions and maintain the stability of the spatial conformation of the antibody variable region; the variable regions of natural heavy chains and light chains each contain four framework region segments (FR1, FR2, FR3, FR4); the structure of the heavy chain variable region is usually HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the structure of the light chain variable region is usually LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.
[0039] Antibody CDRs can be identified using various numbering systems, such as CCG, Kabat, AbM, Chothia, and IMGT. These numbering systems are known in the art. For example, the amino acid sequences of the antigen-binding proteins described herein may be numbered according to the IMGT numbering scheme. V(D)J recombination generates the coding sequence for the variable region (V region), which encodes the variable region (V region) of an antibody molecule, rather than the complete amino acid sequence of the entire antibody heavy or light chain. V(D)J recombination is a gene rearrangement process that occurs during the development of vertebrate B and T cells and is the core mechanism for generating diverse antigen-binding proteins (antibodies and T cell receptors). This process randomly combines V (variable region), D (diversity region), and J (joining region) gene segments to form unique antigen-binding domains, enabling specific recognition of a wide range of pathogens.
[0040] An antibody's "constant region" or "constant domain" (C region) refers to the carboxyl-terminal (C-terminal) domain of an antibody's heavy or light chain. The heavy and light chain constant regions / domains are referred to as "CH" and "CL," respectively. The amino acid sequences of these domains are relatively conserved and primarily carry out the antibody's effector functions. "Fc" (Fragment Crystallizable), "Fc fragment," "Fc region," or "Fc domain" refers to the C-terminal region of an antibody's heavy chain.
[0041] The antibodies of the present invention can be prepared using conventional methods in the art, such as hybridoma technology, phage display technology, and cell line expression, which are well known in the art. The present invention also provides fusion proteins comprising the antibodies or antigen-binding fragments thereof described herein as expression targets, active molecules, or targeting molecules. For example, fusion proteins can be formed by adding tags (e.g., His6 tags) to both ends of the antibody to facilitate protein expression or purification. These tags do not affect the function of the target protein and can be easily removed.
[0042] The present invention also provides polynucleotides encoding the antibodies or antigen-binding fragments thereof described herein. Provided herein are polynucleotides encoding heavy chain variable regions, light chain variable regions, heavy chains, light chains, and complementary determining region segments. The polynucleotides of the present invention may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA, or synthetic DNA. DNA may be single-stranded or double-stranded. The present invention also encompasses degenerate variants of the nucleotide sequence encoding the antibody, antigen-binding fragment thereof, fusion protein, or antibody conjugate, i.e., nucleotide sequences encoding the same amino acid sequence but differing in nucleotide sequence.
[0043] Based on the amino acid sequence and codons, those skilled in the art can easily obtain the coding sequence of the antibody or its fragment. Codon optimization can also be used in the art to modify the expression of polypeptides in different species. The codon preferences of different species are routine in the art.
[0044] In some embodiments, the ELISA kits provided herein may include, in addition to a solid phase carrier pre-coated with the anti-GM antibody, an enzyme-labeled anti-GM antibody, and a compatible enzyme-labeled secondary antibody, enzyme-labeled gentamicin, a solid phase carrier pre-coated with a complete gentamicin antigen, or a solid phase carrier pre-coated with a complete gentamicin antigen. Furthermore, in some embodiments, the ELISA kits provided herein may further include a lysis medium for dissolving the sample, and general reagents and buffers required for detection, such as substrates, blocking solutions, washing solutions, and sample diluents. Of course, these experimental materials can also be prepared independently.
[0045] The present invention will be described below by way of specific examples. It should be understood that these examples are merely illustrative and are not intended to limit the scope of the present invention. The methods and materials used in the examples are, unless otherwise stated, conventional materials and methods in the art.
[0046] Example
[0047] I. Example 1: Preparation of anti-GM antibodies
[0048] 1. Preparation of complete gentamicin antigen
[0049] In the present embodiment, gentamicin (GM) is coupled with bovine serum albumin (BSA) and ovalbumin (OVA) to synthesize the immunogen and coating source of gentamicin, respectively.
[0050] 1.1 Preparation of immunogen
[0051] Gentamycin sulfate and bovine serum albumin (BSA) were added at a molar ratio of 50:1 to 500:1 to prepare the gentamicin immunogen.
[0052] The current embodiment adopts the following proportions to prepare the gentamicin immunogen, and the specific process is as follows:
[0053] Dissolve 1000mg of gentamicin sulfate and 200mg of BSA in 5ml of phosphate buffer (pH 7.4). Dissolve 9mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 5ml of purified water and add dropwise to the gentamicin system. Allow to react at room temperature for 1.5 hours and then at 0-5°C for 3 days. Transfer the reaction solution to a dialysis bag and dialyze against 0.01mol / L phosphate buffer at 4°C for 2 days, changing the dialysate every 6 hours. After dialysis, centrifuge at 4500rpm for 15 minutes at 4°C. Aliquot the solution and store at -80°C for later use.
[0054] 1.2 Preparation of coating
[0055] The coating source of gentamicin was prepared according to the method and steps for preparing the immunogen in the present Example 1.1, except that BSA was replaced with ovalbumin (OVA) and all other conditions remained unchanged.
[0056] 2. Animal immunization
[0057] Four female BALB / C mice aged 6-8 weeks were immunized with the immunogen prepared in 1.1 via multiple subcutaneous injections, biweekly for a total of three immunizations. The immunogen was emulsified in equal volumes of Freund's complete adjuvant for the first immunization; the immunogen was emulsified in equal volumes of Freund's incomplete adjuvant for the second and third immunizations. The dose (50-100 μg / mouse) and method of each immunization remained unchanged. One week after the third immunization, blood was collected from the tail vein of the mice, and the serum titer was determined by indirect ELISA. The titer results of the serum from the immunized mice are shown in Table 1.
[0058] Table 1 Titer and inhibition rate of sera from immunized mice
[0059]
[0060] From mice with qualified serum titers (generally, individuals with an inhibition rate of 90% or higher at 10 ppb of the Qingda standard are considered qualified), the mice with the best inhibition effect are selected for pulse immunization. In the current example, based on the serum titer and inhibition rate data in Table 5, the mice with the best inhibition effect (i.e., mouse 3) among those meeting the criteria are selected for pulse immunization: the immunogen is diluted to 200 μL with 1× PBS (i.e., 0.01 mol / L phosphate buffered saline) and injected intraperitoneally into the selected mice for pulse immunization.
[0061] After the shock immunization, blood was collected from the orbital cavity of the mice and collected in EP tubes. After standing at 37°C for 2 hours, the blood was centrifuged at 4000 rpm for 10 minutes. The serum was collected and used as a positive control for subsequent screening of monoclonal antibodies.
[0062] Three days after the shock immunization, cell fusion can be performed to prepare hybridoma cells.
[0063] 3. Hybridoma cell preparation
[0064] 3.1 Cultivation of SP2 / 0 Myeloma Cells
[0065] Thaw SP2 / 0 myeloma cells by rapid shaking in a 37°C water bath. Aseptically, add the cells to a 50 mL sterile centrifuge tube containing 10 mL of complete culture medium. Centrifuge at 1000 rpm for 5 minutes. Discard the supernatant and resuspend the cells in complete culture medium. Remove 5 mL of culture medium from the resuspended cells and add them to a cell culture flask containing 5 mL of culture medium. Incubate in a CO2 incubator at 37°C. Observe cell growth and status under a microscope. Subculture the SP2 / 0 myeloma cells when the cell density reaches approximately 80%.
[0066] 3.2 Obtaining B lymphocytes
[0067] Selected mice were killed by carbon dioxide asphyxiation followed by cervical dislocation, and their spleens were removed. The mouse spleen was placed in a 15 mL sterile centrifuge tube containing 10 mL of DMEM medium. After moistening the spleen, the excess medium was carefully discarded. 10 mL of DMEM medium was aspirated and placed in a sterile dish. The spleen was ground with a frosted glass slide to create a single-cell suspension. The suspension was then filtered through a 200-mesh nylon mesh into a sterile centrifuge tube. 30 mL of DMEM was added to a 50 mL sterile centrifuge tube. The nylon mesh was rinsed with a pipette. The centrifuge tube containing the spleen cell suspension was centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded, and the cell clumps were gently broken up by hand. The cell clumps were resuspended in 30 mL of DMEM medium and centrifuged again. The supernatant was discarded, and the cell clumps were gently broken up by hand. The cell clumps were then resuspended in 10 mL of DMEM medium.
[0068] 3.3 Cell fusion
[0069] Centrifuge at 1000 rpm for 5 minutes to harvest well-grown SP2 / 0 myeloma cells. Resuspend in 30 mL of DMEM medium. After a second centrifugation, resuspend in 10 mL of DMEM medium. Combine the B lymphocyte suspension with the SP2 / 0 myeloma cell suspension and centrifuge at 1000 rpm for 5 minutes. Discard the supernatant and gently break up the cell clumps. Place in a 37°C water bath. Within 1 minute, pipette 1 mL of PEG fusion agent dropwise into the centrifuge tube. At this point, the cells should resemble a red, homogenous, quicksand-like substance.
[0070] Add 1 mL of preheated DMEM medium within 1 minute, add 1 mL of preheated DMEM medium again within 1 minute, and then add 7 mL of preheated DMEM medium within 3 minutes. Let it stand in a 37°C water bath for 5 minutes, and centrifuge at 800 rpm for 5 minutes to terminate cell fusion.
[0071] The supernatant was discarded, HAT medium was added, the cells were mixed, and the fused cell suspension was evenly spread in a 96-well cell plate with feeder cells added, and the plate was placed in a CO2 cell culture incubator and cultured at 37°C.
[0072] 3.4 Screening of positive hybridoma cells
[0073] Seven days after cell fusion, when relatively large cell clusters are observed, the cell supernatant was assayed using an indirect ELISA. 1 μg / mL of the coating agent (prepared as described in Example 1.2) was used as the assay antigen. The positive control was serum from immunized mice (i.e., serum from the selected mice collected before cell fusion), and the negative control was serum from immunized mice in PBS. Positive wells were retested for inhibition against a gentamicin standard.
[0074] Table 2 Hybridoma cell screening results (cell supernatant within 24 hours)
[0075]
[0076] 3.5 Clonal culture
[0077] The positive hybridoma cells screened were subcloned by limiting dilution method.
[0078] Table 3 Limiting dilution test results (cell supernatant within 24 hours)
[0079]
[0080] The hybridoma cell line 3A3-G3 that was identified after subcloning and could stably secrete monoclonal antibodies was transferred to a cell flask for expansion culture and stored in liquid nitrogen.
[0081] 3.6 Antibody Collection
[0082] When the cell count reached approximately 80%, 10 mL of sterile 1× PBS was added to the culture, the cell layer was blown off, and the pellet was resuspended and transferred to a 15 mL centrifuge tube. Centrifuge at 1000 rpm for 10 minutes, discard the supernatant, and resuspend the pellet in 1 mL of sterile 1× PBS to mix thoroughly. Each mouse was injected with 500 μL of the cell suspension, and the mice's growth was observed. After one week, when the abdomen of the mouse had swelled, ascites was collected into a centrifuge tube. Centrifuge at 8000 rpm for 20 minutes, and the ascites layer was aspirated. Crude purification was performed using the octanoic acid-ammonium sulfate method. The crudely purified monoclonal antibody was then purified using a prepacked Protein G column to obtain the anti-gentamicin monoclonal antibody 3A3-G3, also known as the anti-GM monoclonal antibody 3A3-G3.
[0083] 4. Identification and performance testing of anti-GM monoclonal antibody 3A3-G3
[0084] 4.1 SDS-PAGE identification
[0085] The concentration of anti-GM monoclonal antibody 3A3-G3 was measured using a microspectrophotometer and was found to be 8.3 mg / mL.
[0086] Anti-GM monoclonal antibody 3A3-G3 was analyzed by SDS-PAGE electrophoresis. Figure 1 As shown, two distinct bands appeared near 25 kDa and 50 kDa: the antibody light chain at 25 kDa and the antibody heavy chain at 50 kDa, with no other contaminants. Analysis by Fiji software indicated that the purity of anti-GM monoclonal antibody 3A3-G3 reached 95%.
[0087] 4.2 Sensitivity test of anti-GM monoclonal antibody 3A3-G3
[0088] The sensitivity of the anti-GM monoclonal antibody 3A3-G3 was tested using an indirect ELISA method. The coating agent (prepared as described in Example 1.2) was coated at a concentration of 1 μg / mL. The initial concentration of 1 mg / mL of anti-GM monoclonal antibody 3A3-G3 was diluted to 10 μg / mL, 1 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL, 0.0625 μg / mL, and 0.03125 μg / mL, respectively. The sensitivity of anti-GM monoclonal antibody 3A3-G3 was determined using an indirect ELISA method. The results are shown in Table 4. The sensitivity of anti-GM monoclonal antibody 3A3-G3 was as high as 88.73% at 0.0625 μg / mL.
[0089] Table 4 Sensitivity test results of anti-GM monoclonal antibody 3A3-G3
[0090]
[0091] 4.3 Specificity test of anti-GM monoclonal antibody 3A3-G3
[0092] The specificity of the anti-GM monoclonal antibody 3A3-G3 was tested using an indirect ELISA method. The coating material prepared according to the method and steps of Example 1.2 was used as a complete gentamicin antigen. It was also coated with complete antigens of kanamycin, streptomycin, lincomycin, and erythromycin at 1 μg / mL. The initial concentration of 1 mg / mL of anti-GM monoclonal antibody 3A3-G3 was diluted to 0.0625 μg / mL to verify its specificity. The results are shown in Table 5. Anti-GM monoclonal antibody 3A3-G3 reacted specifically with the complete gentamicin antigen, but not with the complete antigens of kanamycin, streptomycin, lincomycin, and erythromycin, demonstrating good specificity and no cross-reactivity.
[0093] Table 5 Specificity test results of anti-GM monoclonal antibody 3A3-G3
[0094]
[0095] 4.4 Sequencing of anti-GM monoclonal antibody 3A3-G3
[0096] The subcloned cell line of the anti-GM monoclonal antibody 3A3-G3 was sent to Sangon for sequencing. Antibody sequencing was performed by Sanger / NGS sequencing to obtain the V region amino acid sequence and related nucleotide sequence of the anti-GM monoclonal antibody 3A3-G3.
[0097] This example uses V(D)J-IMGT to describe antibody V region gene recombination and its amino acid sequence. "V(D)J-IMGT" is a standardized term in the field of immunogenetics, specifically referring to a systematic framework established by the International Immunogenetics Database (IMGT) for describing and analyzing antibody variable region (V region) gene recombination (V(D)J rearrangement) and its encoded amino acid sequence.
[0098] Among them, the variable region (V region) amino acid sequence and its corresponding nucleotide sequence of the anti-GM monoclonal antibody 3A3-G3 are as follows:
[0099] Heavy chain variable region (VH):
[0100] HCDR1 amino acid sequence (SEQ ID No. 1):
[0101] GFTFSHYA;
[0102] HCDR2 amino acid sequence (SEQ ID No. 2):
[0103] ITAAGTYT;
[0104] HCDR3 amino acid sequence (SEQ ID No. 3):
[0105] VRQGGFYSHYFAY;
[0106] The full-length amino acid sequence of the heavy chain variable region (SEQ ID No. 7):
[0107] QVQLQESGGGLVKPGGSLKLSCAASGFTFSHYAMSWVRQTPEKRLEWVATITAAGTYTYYLDSVRGRFTISRDNGNNTLFLKMSSLRSEDTAMYYCVRQGGFYSHYFAYWGQGTALTVSS;
[0108] And its corresponding nucleotide sequence (SEQ ID No.9):
[0109] CAGGTCCAGCTGCAGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTCACTATGCCATGTCCTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATCACTGCTGCTGGTACTTACACCTACTAT CTAGACAGTGTGAGGGGTCGATTCACCATCTCCAGAGACAATGGCAATAATACCCTGTTCCTGAAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGTAAGACAAGGGGGTTTCTATTCACACTACTTTGCCTATTGGGGCCAAGGCACCGCTCTCACAGTCTCCTCA;
[0110] Light chain variable region (VL):
[0111] LCDR1 amino acid sequence (SEQ ID No. 4):
[0112] SSVSY;
[0113] LCDR2 amino acid sequence (SEQ ID No. 5):
[0114] DTS;
[0115] LCDR3 amino acid sequence (SEQ ID No. 6):
[0116] QQWSSNPYT;
[0117] Full-length amino acid sequence of the light chain variable region (SEQ ID No. 8):
[0118] DIVITQTPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPYTFGGGTKLEIK;
[0119] and its corresponding nucleotide sequence (SEQ ID No.10):
[0120] GACATTTGTGATCACACAAACTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAAGTTACATGCACTGGTACCAGCAGAAGTCAGGCACCTCCCCAAAAGATGGATTTATGACACATCCAAACTG GCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTGGAGTAGTAACCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA.
[0121] II. Example 2: Preparation of a Gentamicin (GM) Residue Detection Kit
[0122] To further illustrate the application prospects and key role of the anti-GM antibodies provided by the present invention in the field of immunoassay technology, the current example constructs a gentamicin (GM) residue rapid detection kit (colloidal gold immunochromatography) based on the anti-GM monoclonal antibody 3A3-G3 provided in Example 1, which is used for the rapid detection of gentamicin residues in the sample to be tested.
[0123] For the aforementioned gentamicin (GM) residue rapid detection kit (colloidal gold immunochromatography), for the sake of convenience, it will be referred to as the gentamicin (GM) rapid detection kit below, and its preparation process is as follows.
[0124] 1. Preparation of Gentamicin (GM) Rapid Test Kit
[0125] 1.1 Preparation of colloidal gold markers
[0126] In the present embodiment, the anti-GM monoclonal antibody 3A3-G3 of Example 1 is selected to prepare the colloidal gold label required for the gentamicin (GM) rapid test kit. The specific preparation process is as follows:
[0127] Add chloroauric acid (2 mL, 1%) to ultrapure water, bring the water to a boil with rapid stirring, and add a reducing agent, trisodium citrate (4 mL, 1.2%), to react and prepare colloidal gold;
[0128] Anti-GM monoclonal antibody 3A3-G3 was added to colloidal gold at a ratio of 20 μg antibody / mL colloidal gold (antibody was added dropwise at room temperature, 200 rpm, pH 7.5). Blocking and stabilization were performed (blocking agent (1% bovine serum albumin or 0.05% casein) was added to the final concentration and stirring was continued for 30 minutes to prevent aggregation). After the colloidal gold label of anti-GM monoclonal antibody 3A3-G3 was formed, the solution was purified by centrifugation (12,000 g for 30 minutes at 4°C and the supernatant was discarded) and resuspended for storage (the pellet was resuspended to 1 / 10 of the original volume in 0.01 mol / L PBS (pH 7.4) containing 1% BSA and 5% sucrose) for later use.
[0129] 1.2 Preparation of immunochromatographic test strips
[0130] (1) Preparation of sample pad
[0131] The highly absorbent material used to prepare the sample pad was soaked in a 0.1 mol / L phosphate buffer solution containing 0.5% BSA, pH 7.2 for 2 h, and dried at 37°C for 2 h to obtain a sample pad assembly.
[0132] (2) Preparation of gold label pad
[0133] A glass fiber membrane was used to prepare the binding pad (i.e., gold-labeled pad). Before preparation, it was pretreated by immersing it in a buffer solution (containing 1% BSA, 0.5% Triton X-100, and 1% sucrose) and drying it (37°C for 12 hours) to reduce nonspecific adsorption.
[0134] During the process of coating the conjugate pad with colloidal gold marker, the colloidal gold marker of the anti-GM monoclonal antibody 3A3-G3 was evenly sprayed at a linear flow rate (10 μL / cm) using a film dispenser and dried at 37° C. for 24 h to obtain a gold marker pad assembly.
[0135] (3) Preparation of chromatography membrane
[0136] The coating source (prepared according to the method and steps in 1.2 of Example 1) was coated on the test line (T line) on the chromatographic membrane using a film spotter. The secondary antibody compatible with the anti-GM monoclonal antibody 3A3-G3 (considered as the primary antibody) was coated on the quality control line (C line) on the chromatographic membrane using a film spotter. After coating, the chromatographic membrane was dried at 37°C for 2 hours to obtain the chromatographic membrane assembly.
[0137] (4) Assembling immunochromatographic test strips
[0138] The sample pad assembly, the gold label pad assembly, the chromatography membrane assembly, and the absorbent pad are sequentially adhered to a PVC base plate; the starting end of the sample pad assembly is aligned with the starting end of the base plate, the end of the sample pad assembly is overlapped with the starting end of the gold label pad assembly by 1 to 3 mm, the end of the gold label pad assembly is overlapped with the starting end of the chromatography membrane assembly by 1 to 3 mm, the end of the chromatography membrane assembly is overlapped with the starting end of the absorbent pad by 1 to 3 mm, and the end of the absorbent pad is aligned with the end of the base plate; the assembled immunochromatographic test paper template is cut into appropriate widths to obtain an immunochromatographic test paper strip for detection.
[0139] 1.3 Assembling the Gentamicin (GM) Rapid Test Kit
[0140] By packaging the above-mentioned immunochromatographic test strips, you can obtain a gentamicin (GM) rapid test kit.
[0141] 2. Performance Verification of Gentamicin (GM) Rapid Test Kit
[0142] The basic performance of the gentamicin (GM) rapid test kit of the current embodiment was verified based on the results of a gold label reader (also known as an immunochromatographic reader or colloidal gold card reader) and supplemented by naked eye interpretation.
[0143] 2.1 Sensitivity test of gentamicin (GM) rapid test kit
[0144] Gentamicin standards were diluted to 5 ppb (ppb is a dimensionless unit commonly used in food safety residue testing; in aqueous solutions, 1 ppb corresponds to 1 ng / mL) and 10 ppb. Several gentamicin (GM) rapid test kits prepared in this example were used to test spiked milk samples to verify their sensitivity. The results are detailed in Table 6. The results demonstrate that the gentamicin (GM) rapid test kits used in the current sensitivity testing and their products from the same batch have high sensitivity, with a minimum detection limit of 10 ppb for the gentamicin standard.
[0145] Table 6 Sensitivity test results of gentamicin (GM) rapid test kit
[0146]
[0147] 2.2 Gentamicin (GM) Rapid Test Kit Specificity Test
[0148] Some gentamicin (GM) rapid test kits prepared in this example were used to test 500 ppb of gentamicin, kanamycin, streptomycin, lincomycin, and erythromycin spiked milk samples to verify their specificity. The results are detailed in Figure 2The results showed that the gentamicin (GM) rapid test kit used for the current specificity test and its products from the same batch not only did not cross-react with non-aminoglycoside antibiotics such as lincomycin and erythromycin, but also did not cross-react with aminoglycoside antibiotics such as kanamycin and streptomycin. It has good specificity and is suitable for specific detection targeting only gentamicin (GM) residues.
[0149] 3. Example 3: Application of Gentamycin (GM) Residue Detection Kit
[0150] Considering the urgent need for gentamicin residue detection in antibiotic residue analysis in fields such as food safety monitoring and environmental pollution monitoring, the gentamicin (GM) rapid test kit in Example 2 can be applied to related tests. Therefore, the current example applies the gentamicin (GM) rapid test kit in Example 2 to the detection of gentamicin (GM) residues in samples to be tested in the fields of food safety monitoring and environmental pollution monitoring.
[0151] 1. Matrix verification and sample processing
[0152] Matrix validation and sample preparation for gentamicin (GM) rapid test kits are essential prerequisites for ensuring the accuracy and reliability of test results. "Matrix" refers to all background substances in the sample other than the target substance. Its core influence is the matrix effect, whereby matrix interference other than the target substance in the sample interferes with the test results, causing the measured value to deviate from the true value. Spiking experiments are the most direct and effective method for matrix validation.
[0153] For unverified matrices, before using the Gentamicin (GM) Rapid Test Kit for gentamicin residue detection, dilute the gentamicin standard to 5ppb or 10ppb (i.e., the detection limit of the Gentamicin (GM) Rapid Test Kit) based on its sensitivity, and perform spiked detection on the samples to be tested to perform matrix verification; for samples that are determined to have no matrix interference, the Gentamicin (GM) Rapid Test Kit can be used to detect gentamicin residues in such samples.
[0154] Sample processing aims to adapt the collected original sample to the detection conditions of the gentamicin (GM) rapid test kit of the current embodiment. The gentamicin (GM) rapid test kit is primarily suitable for liquid samples. Therefore, sample processing in the current embodiment includes, but is not limited to: preparing original samples in solid or other non-liquid form into liquid form that can be detected by the gentamicin (GM) rapid test kit; diluting samples with excessively high residual gentamicin (GM) concentrations; and removing interfering substances from original samples through methods such as filtration, centrifugation, and digestion.
[0155] 2. Rapid sample testing
[0156] Return the sample to be tested and the immunochromatographic test strips and other reagents (required number) in the gentamicin (GM) rapid test kit to room temperature (20-25°C); place 200 μL of the sample to be tested on the sample pad, and determine the test result by the color development of the immunochromatographic test strips through chromatography and incubation with colloidal gold markers.
[0157] 3. Determination of test results
[0158] As a rapid test based on antigen-antibody binding, the gentamicin (GM) rapid test kit supports rapid interpretation by the naked eye. This means the test result is determined by visually identifying the color of the test line (T line) and control line (C line) on the chromatographic membrane. The identification criteria are as follows.
[0159] Negative (chromogenic characteristics): Both C-line and T-line are colored, and the color of T-line is stronger than that of C-line;
[0160] A negative result indicates that the residual concentration of gentamicin in the sample is below the detection limit;
[0161] Positive (color characteristics): C line is colored, the color of C line is the same as that of T line, the color of T line is weaker than that of C line, or T line is not colored;
[0162] A positive result indicates that the concentration of gentamicin residue in the sample is equal to or higher than the detection limit.
[0163] Invalid (color characteristics): no C line appears;
[0164] Invalid results indicate incorrect operation or that the immunochromatographic test strip has deteriorated and become invalid.
Claims
1. An anti-GM antibody targeting a gentamicin antigen epitope, characterized in that: It includes: HCDR1, HCDR2, HCDR3; and / or, LCDR1, LCDR2, LCDR3; in, The amino acid sequence of the HCDR1 is shown in SEQ ID No. 1; The amino acid sequence of the HCDR2 is shown in SEQ ID No. 2; The amino acid sequence of the HCDR3 is shown in SEQ ID No. 3; The amino acid sequence of the LCDR1 is shown in SEQ ID No. 4; The amino acid sequence of the LCDR2 is shown in SEQ ID No. 5; The amino acid sequence of the LCDR3 is shown in SEQ ID No.
6.
2. The anti-GM antibody according to claim 1, wherein The heavy chain variable region of the anti-GM antibody comprises a heavy chain variable region framework region; the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 7; and / or, The light chain variable region of the anti-GM antibody comprises a light chain variable region framework region; the amino acid sequence of the light chain variable region is shown in SEQ ID No.
8.
3. The anti-GM antibody according to claim 1, wherein The anti-GM antibody further comprises a heavy chain constant region and / or a light chain constant region; and / or, The anti-GM antibody is a mouse antibody.
4. A polynucleotide encoding the anti-GM antibody according to any one of claims 1 to 3.
5. The polynucleotide according to claim 4, wherein It includes: A nucleotide fragment encoding the heavy chain variable region of the anti-GM antibody according to claim 2, the sequence of which is shown in SEQ ID No. 9; and / or, A nucleotide fragment encoding the light chain variable region of the anti-GM antibody according to claim 2, the sequence of which is shown in SEQ ID No.
10.
6. A kit for detecting gentamicin residues, characterized in that: It includes: The anti-GM antibody according to any one of claims 1 to 3; and a reagent for detecting the binding of free gentamicin to the anti-GM antibody.
7. The kit for detecting gentamicin residues according to claim 6, wherein The test kit for detecting gentamicin residues is an ELISA test kit; The ELISA kit includes: a solid phase carrier pre-coated with the anti-GM antibody; or, the enzyme-labeled anti-GM antibody; or, The anti-GM antibody and its compatible enzyme-labeled secondary antibody.
8. The kit for detecting gentamicin residues according to claim 6, wherein The kit for detecting gentamicin residues is an immunochromatographic kit; The immunochromatography kit comprises: an immunochromatography test strip; Wherein, the immunochromatographic test kit is coated with a marker through the binding pad / binding area of the immunochromatographic test strip or independently loaded with a marker; The marker is an anti-GM antibody labeled with colorimetric or fluorescent nanoparticles; Wherein, the color-developing nanoparticles are colloidal gold, colloidal carbon or latex microspheres; and the fluorescent nanoparticles are quantum dots or fluorescent microspheres.
9. A non-diagnostic method for detecting gentamicin residues, characterized in that It includes: The anti-GM antibody according to any one of claims 1 to 3 or the anti-GM antibody in the kit for detecting gentamicin residues according to any one of claims 6 to 8 is incubated with the sample to be tested, and the binding of free gentamicin in the sample to be tested and the anti-GM antibody is detected to determine the gentamicin residue in the sample to be tested.
10. Use of the anti-GM antibody according to any one of claims 1 to 3, the polynucleotide according to any one of claims 4 to 5, the kit for detecting gentamicin residues according to any one of claims 6 to 8, or the non-diagnostic method for detecting gentamicin residues according to claim 9 in food safety supervision / environmental pollution monitoring.
Citation Information
Patent Citations
Monoclonal antibody for detecting aminoglycoside antibiotics and kit thereof
CN102776151A
Gentamicin residue diagnosis strip and application thereof
CN105004844A
Core amino acid sequence for targeted recognition of gentamicin single-chain antibody and application thereof
CN110563807A
